1.Introduction

For most of the modern history of iron supplementation, the operating assumption has been straightforward: identify a deficit in serum ferritin, and deliver enough elemental iron to close it. This assumption is not wrong, but it is incomplete. Iron is one of the most tightly regulated micronutrients in human physiology, and how much of a given dose is actually absorbed, transported, and incorporated into new red blood cells is governed by mechanisms that operate largely independent of dose size alone [1,2].

This review examines the physiological rationale for a multi-pathway approach to iron supplementation, organized around the ingredients used in Iron Evolution™: an iron source designed for tolerability and bioavailability, a cofactor supporting its chemical conversion, transport proteins that move iron through the body, substrates required for red blood cell production, and a mechanism addressing the inflammatory signaling that can suppress iron utilization regardless of how much iron is supplied.

Two clarifications are worth making before proceeding. First, this review distinguishes throughout between iron delivery (how much iron reaches the gut or bloodstream) and iron utilization (whether that iron is absorbed, transported, and incorporated into hemoglobin) — a distinction with substantial support in the hematology literature [1–4]. Second, this is a review of the mechanistic and clinical evidence for each individual ingredient and pathway; it is not a clinical trial of the finished Iron Evolution™ formulation, and no such trial is claimed to exist. Where the literature has tested combinations of these ingredients, that is noted; where evidence for a specific combination is preliminary or absent, that is stated directly rather than implied otherwise.

2.The Hepcidin–Ferroportin Axis: Why Delivery Isn't the Whole Story

Systemic iron balance is governed chiefly by hepcidin, a peptide hormone produced by the liver that binds to ferroportin — the only known iron export channel in humans — and triggers its internalization and degradation [1,3,4]. Ferroportin sits on the surface of intestinal enterocytes, macrophages that recycle iron from senescent red blood cells, and iron-storing hepatocytes; when hepcidin degrades ferroportin at these sites, iron already inside the cell cannot be exported into plasma, regardless of how much iron was supplied in the first place [3,4]. Structural work published in Nature has shown that hepcidin's binding affinity for ferroportin increases roughly 80-fold in the presence of iron, meaning the system is specifically tuned to block export from iron-loaded cells [3].

Hepcidin production rises in response to two separate signals: elevated body iron stores, and inflammation [1,4]. The inflammatory pathway runs through interleukin-6 (IL-6). A foundational 2004 study in the Journal of Clinical Investigation demonstrated, across human liver cell cultures, mouse models, and human volunteers, that IL-6 is both necessary and sufficient to induce hepcidin synthesis during inflammation, and that this IL-6–hepcidin axis is directly responsible for the hypoferremia (low blood iron) seen in inflammatory states [2]. This is the mechanistic basis for a well-established clinical phenomenon: iron delivered to someone with an elevated inflammatory burden can be poorly utilized even when absorption itself is otherwise unimpaired, because hepcidin is actively blocking its export from storage [2,4].

This axis is the physiological rationale connecting two otherwise separate ingredients in Iron Evolution™ — lactoferrin and the astaxanthin-led carotenoid complex — to iron utilization specifically, discussed in Sections 8 and 10.

3.Ferrochel® (Ferrous Bisglycinate Chelate): Evidence for Bioavailability and Tolerability

Ferrochel®, a ferrous iron chelated to two glycine molecules, was developed specifically to address the two persistent problems of inorganic iron salts (ferrous sulfate, ferrous fumarate, ferrous gluconate): poor and variable absorption, and gastrointestinal intolerance driven by unchaperoned free iron in the gut [5,6].

Absorption. A controlled human bioavailability study published in The Journal of Nutrition fortified breakfast breads with iron bis-glycine chelate and compared absorption against ferrous sulfate and iron-EDTA using isotope-labeled iron across 74 subjects in five experiments; iron absorption from the bis-glycine chelate was approximately twice that from ferrous sulfate (p < 0.05) [5]. A separate randomized trial in pregnant women found that a substantially lower elemental-iron dose of ferrous bisglycinate (15 mg/day) performed comparably to a much higher dose of ferrous sulfate (40 mg/day) in correcting iron deficiency, consistent with materially higher per-milligram bioavailability [7].

Tolerability. A registered, industry-sponsored multicenter randomized trial compared ferrous bisglycinate chelate against ferrous ascorbate for efficacy and tolerability in iron-deficiency anemia [9]. More recently, a randomized noninferiority trial in Cambodian women found that an 18-mg elemental dose of ferrous bisglycinate was noninferior to a 60-mg dose of ferrous sulfate for raising ferritin, while additionally showing reduced gut inflammation markers and enteropathogen detection at the lower, chelated dose [8]. A dedicated toxicology program — an acute oral toxicity study, a 14-day repeated-dose study, and a 90-day subchronic toxicity study in rats — found no biologically or statistically significant adverse findings across body weight, hematology, and organ pathology at doses well above typical human intake, supporting the safety profile of the chelate [6].

Considered together, this body of evidence supports ferrous bisglycinate chelate as a well-studied alternative to inorganic iron salts, with a materially different absorption and tolerability profile rather than a marginal improvement.

4.Liposomal Encapsulation: Evidence for Enhanced Delivery

Liposomal encapsulation surrounds a nutrient in a phospholipid bilayer designed to mimic a biological cell membrane, in principle protecting the payload from degradation and gastric irritation while facilitating absorption through membrane-associated transport pathways [10–12].

Mineral absorption generally. A randomized crossover trial published in Nutrients (Texas Tech University) compared a liposomal multivitamin/mineral product against a nutrient-matched standard formulation in 25 healthy adults, measuring blood iron and magnesium concentrations at multiple time points after ingestion. The liposomal condition showed statistically significant advantages in iron pharmacokinetics at 4 hours (+14.3% vs. −6.0% from baseline, p = 0.0001) and 6 hours (+1.0% vs. −21.0%, p = 0.0002) post-ingestion compared to the standard formulation [10].

Iron-deficiency anemia specifically. Multiple randomized controlled trials, predominantly in pediatric populations, have compared liposomal iron (most commonly as ferric pyrophosphate) against conventional oral iron salts or intravenous iron for treating iron-deficiency anemia, generally reporting comparable or superior improvements in hemoglobin and iron indices alongside meaningfully fewer gastrointestinal side effects [11,12]. A systematic review and meta-analysis of these pediatric randomized trials concluded that liposomal iron delivery systems represent a viable strategy for improving both bioavailability and gastrointestinal tolerability relative to conventional iron [11].

5.Combining Chelation and Encapsulation: What the Combined Literature Shows

Iron Evolution™ uses liposome-encapsulated ferrous bisglycinate chelate — pairing a chelation form already associated with improved tolerability on its own with a delivery technology associated with further protection and improved uptake. This is best understood as two independently evidenced mechanisms layered together, rather than a single mechanism with its own dedicated clinical trial base.

The most directly relevant available evidence is a laboratory study using the Caco-2 human intestinal cell model, which evaluated iron transport specifically from liposome-encapsulated ferrous glycinate, examining how known dietary inhibitors of iron absorption (phytic acid, zinc) and liposome particle size affected transport [13]. This model demonstrated that liposomal encapsulation measurably alters the transport behavior of the chelated iron, and that inhibitory compounds still reduced transport in a concentration-dependent manner — useful groundwork, but a laboratory cell-model result, not a human clinical trial of the combined ingredient.

6.Vitamin C: Mechanism and Evidence for Enhanced Non-Heme Iron Absorption

Iron exists in two oxidation states relevant to human absorption: ferric (Fe³⁺) and ferrous (Fe²⁺). Only the ferrous form is efficiently transported across the intestinal brush border by the divalent metal transporter DMT1 [14]. Ascorbic acid (vitamin C) acts as a reducing agent, converting ferric iron to the ferrous form, and additionally forms a soluble chelate with iron that resists precipitation as it moves from the acidic stomach into the more alkaline duodenum [14].

Single-meal evidence. The enhancing effect of ascorbic acid on non-heme iron absorption from single test meals is one of the most consistently replicated findings in iron nutrition research; a synthesis of short-term absorption trials found a mean increase in iron absorption of approximately 5.87 percentage points when ascorbic acid was added to test meals [15]. Classic dose-ranging work found the increase in absorption to be roughly proportional to the amount of ascorbic acid added across a wide range of doses [14].

7.Copper and the Ferroxidase System: Ceruloplasmin, Hephaestin, and Iron Export

Iron cannot simply diffuse out of cells into the bloodstream; ferrous iron exported through ferroportin must be oxidized to the ferric form to bind its plasma carrier protein, transferrin, and this oxidation step depends on copper-containing enzymes [16–18].

Two multicopper ferroxidases carry out this function: hephaestin, a membrane-bound enzyme expressed in intestinal enterocytes, and ceruloplasmin, a copper-dependent protein produced by the liver and released into circulation [16–18]. Hephaestin was identified through study of the sla mouse, an animal model with a genetic defect in intestinal iron export; these mice absorb iron into intestinal cells normally but cannot move it into circulation, and the causative gene — a ceruloplasmin homologue highly expressed in the intestine — was identified and published in Nature Genetics [16]. Knockout studies of both hephaestin and ceruloplasmin together produce severe systemic iron deficiency and disrupted iron homeostasis despite normal dietary iron intake, directly demonstrating that copper-dependent ferroxidase activity, not iron delivery, is the rate-limiting step in these animal models [17,18]. A comprehensive physiological review in Comprehensive Physiology describes copper deficiency's historical link to impaired iron metabolism, tracing recognition of this connection back roughly a century, well before the specific enzymes involved were identified [18].

This body of evidence establishes copper as a required cofactor for iron export at both the intestinal and systemic level — a mechanism distinct from, and downstream of, iron absorption itself.

8.Lactoferrin: Iron Transport, Tolerability, and an Anti-Inflammatory Signal

Lactoferrin is an iron-binding glycoprotein, naturally present in human milk, that binds iron through a regulated, receptor-mediated pathway rather than delivering it as free ionic iron [19,20].

Comparative efficacy. A systematic review and meta-analysis of clinical trials comparing oral lactoferrin against ferrous sulfate for iron-deficiency anemia found lactoferrin supplementation associated with significantly better outcomes on serum iron (weighted mean difference 41.44 μg/dL), ferritin (WMD 13.60 ng/mL), and hemoglobin, while noting that lactoferrin's iron-enhancing mechanism appears to operate substantially through anti-inflammatory effects rather than through a large direct increase in iron absorption per se [19]. A controlled absorption study using recombinant human lactoferrin found iron absorption from lactoferrin to be comparable to iron absorption from ferrous sulfate in young women, despite the very different delivery mechanism [20].

The inflammatory connection. This is where lactoferrin's evidence base connects directly to the hepcidin axis described in Section 2. A randomized clinical trial in children with inflammatory bowel disease and iron-deficiency anemia compared lactoferrin (100 mg/day) against ferrous sulfate over three months, measuring interleukin-6 and hepcidin-25 alongside standard iron parameters. Lactoferrin produced significantly greater improvements in hemoglobin, serum iron, transferrin saturation, and ferritin than ferrous sulfate, and — notably — significantly decreased both IL-6 and hepcidin levels, while ferrous sulfate did not [21]. This is one of the more direct pieces of clinical evidence in this review connecting a specific ingredient to a measured reduction in hepcidin itself, rather than to iron status alone.

9.Vitamin B12 and Folate: Substrates for Erythropoiesis

Iron is a necessary but not sufficient input for building new red blood cells. Erythroblasts — the precursor cells that mature into red blood cells in bone marrow — require adequate DNA synthesis to proliferate and differentiate, and this process depends on folate and vitamin B12 as cofactors in purine and thymidylate synthesis [22,23]. When either nutrient is deficient, DNA synthesis is impaired, erythroblasts undergo apoptosis at an increased rate, and red blood cell production becomes ineffective — a well-characterized clinical entity known as megaloblastic anemia, in which precursor cells fail to mature normally regardless of iron availability [22,23]. Because B12 is required to regenerate usable folate from its 5-methyltetrahydrofolate storage form (the basis of the so-called "methyl-folate trap"), deficiency in either nutrient can produce overlapping hematological effects, and combined deficiency of both has been documented to produce severe pancytopenia that resolves with vitamin replacement alone [23]. This is well-established, textbook hematology rather than an emerging or contested finding; it is included here because it explains why an iron-focused formulation without adequate B12 and folate support can still produce impaired red blood cell output even when iron delivery itself is adequate.

10.Astaxanthin, Inflammation, and the Hepcidin Connection

The rationale for including a natural astaxanthin-led carotenoid complex (NatAxtin®) in a formulation focused on iron utilization rests on the inflammatory pathway described in Section 2, and the evidence here is best understood as connecting several separate lines of research rather than a single study measuring the full chain from astaxanthin intake to iron utilization outcomes.

Astaxanthin and IL-6 specifically. A 2024 study in Food & Function examined astaxanthin's effect on lipopolysaccharide-stimulated human macrophages and found that astaxanthin directly targets IL-6 signaling, reducing the inflammatory cytokine cascade these cells produce [24]. This is a cell-culture (in vitro) finding rather than a human clinical measurement, and it should be weighted accordingly — it demonstrates a plausible mechanism, not a demonstrated clinical outcome on its own.

Astaxanthin's anti-inflammatory effects in humans. A recent systematic review of human clinical trials found consistent evidence that astaxanthin supplementation reduces circulating levels of pro-inflammatory markers including IL-6, TNF-α, and CRP across multiple clinical contexts, with one trial in community-acquired pneumonia patients reporting significant reductions in these markers alongside improved clinical severity scores [25]. This establishes that astaxanthin's IL-6-lowering effect, observed at the cellular level, is also observed in human blood in other inflammatory conditions — though not yet in a study specifically measuring hepcidin or iron utilization as the outcome.

Astaxanthin and blood parameters directly. The most directly relevant human evidence identified is a randomized controlled trial in head and neck cancer patients receiving cisplatin chemotherapy (a treatment known to cause anemia through oxidative myelosuppression), which found that astaxanthin supplementation (8 mg/day) was associated with significantly better preservation of hemoglobin and erythrocyte counts compared to a vitamin C and E control (p = 0.012 and p = 0.04, respectively) [26]. This trial's proposed mechanism centers on antioxidant protection of erythropoiesis in a chemotherapy context, which is a related but distinct mechanism from the hepcidin pathway central to this review; it is included because it is the most direct human evidence connecting astaxanthin supplementation to blood-count outcomes, even though the population and proposed mechanism differ from the general iron-deficiency context this formulation targets.

11.Discussion: A Systems View of Iron Utilization

Taken together, this literature supports a broader reframing than "how much iron was delivered." Absorption depends on the chemical form of iron and its readiness for transport (Sections 3, 6); delivery technology can further influence how intact that iron remains until the point of absorption (Sections 4, 5); export from cells into circulation depends on copper-dependent ferroxidases regardless of how much iron sits inside the cell (Section 7); circulating iron only becomes new red blood cells if adequate B12 and folate support DNA synthesis in the bone marrow (Section 9); and all of the above can be functionally overridden by hepcidin during active inflammation, a signal that lactoferrin has direct clinical evidence of modulating and that astaxanthin has a mechanistically plausible, if not yet directly demonstrated, role in addressing (Sections 2, 8, 10).

This is consistent with how iron metabolism is now generally understood in the hematology literature — as a tightly regulated, multi-node system rather than a single reservoir that fills in proportion to intake [1,3,4,18]. A formulation built around one node of that system (elemental iron dose) addresses only one part of a larger regulatory network; a formulation addressing multiple nodes has a stronger mechanistic case for supporting utilization, not merely delivery — while still requiring, ultimately, direct clinical evaluation of the combined formulation to confirm that the sum performs as the parts suggest.

13.Conclusion

The evidence reviewed here supports a central claim of this dossier: that iron status is governed by a network of absorption, transport, production, and inflammatory-regulatory mechanisms, not by elemental iron dose alone. Each ingredient in Iron Evolution™ corresponds to a specific, published mechanism within that network — some resting on decades of converging molecular biology and clinical trials, others resting on a smaller, more preclinical evidence base that is honestly represented as such throughout this review. Bioavailability without utilization is, on the evidence assembled here, a real and well-documented gap — and closing it appears to require addressing more than one point in the system.